122 related articles for article (PubMed ID: 7678359)
21. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
Guthman DA; Wilson TM; Blute ML; Bergstralh EJ; Zincke H; Oesterling JE
Urology; 1993 Aug; 42(2):150-4. PubMed ID: 7690170
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men.
Kakehi Y; Kamoto T; Ogawa O; Kato T; Tobisu K; Akakura K; Egawa S; Usami M; Maeda O; Arai Y; Sumiyoshi Y; Kamiryo Y; Yoshida O
Eur Urol; 2000 May; 37(5):552-8. PubMed ID: 10765093
[TBL] [Abstract][Full Text] [Related]
23. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
Shinohara K; Wolf JS; Narayan P; Carroll PR
J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447
[TBL] [Abstract][Full Text] [Related]
24. Staging prostate cancer--1997: current methods and limitations.
Bostwick DG
Eur Urol; 1997; 32 Suppl 3():2-14. PubMed ID: 9267781
[TBL] [Abstract][Full Text] [Related]
25. Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer.
Furuya Y; Fuse H; Nagakawa O; Masai M
Int J Clin Oncol; 2002 Apr; 7(2):109-13. PubMed ID: 12018107
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.
Ferguson JK; Bostwick DG; Suman V; Zincke H; Oesterling JE
Eur Urol; 1995; 27(1):8-12. PubMed ID: 7538082
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.
Douglas TH; McLeod DG; Mostofi FK; Mooneyhan R; Connelly R; Moul JW; Sesterhenn IA
Prostate; 1997 Jun; 32(1):59-64. PubMed ID: 9207958
[TBL] [Abstract][Full Text] [Related]
28. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
29. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
30. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
33. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
34. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
Carter HB; Sauvageot J; Walsh PC; Epstein JI
J Urol; 1997 Jun; 157(6):2206-9. PubMed ID: 9146616
[TBL] [Abstract][Full Text] [Related]
36. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
37. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Ennis RD; Flynn SD; Fischer DB; Peschel RE
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):317-22. PubMed ID: 7523342
[TBL] [Abstract][Full Text] [Related]
38. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL; Blute ML; Lerner SE; Bergstralh EJ; Bostwick DG; Zincke H
Mayo Clin Proc; 1998 May; 73(5):401-6. PubMed ID: 9581578
[TBL] [Abstract][Full Text] [Related]
39. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
40. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.
Bostwick DG; Qian J; Bergstralh E; Dundore P; Dugan J; Myers RP; Oesterling JE
J Urol; 1996 Apr; 155(4):1361-7. PubMed ID: 8632575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
